DeLiver Pharma ApS: Financial statements 2019
CVR: 39432714
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
DeLiver Pharma ApS (CVR 39432714) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 79,000 and a net result of DKK -12,094. The profit margin was -15.3%. Equity in the 2019 report amounted to DKK 219,581. The solvency ratio was 95.3%.
- Revenue
- DKK 79,000
- Gross Profit
- DKK 50,802
- Profit/Loss
- DKK -12,094
- Equity
- DKK 219,581
- Total Assets
- DKK 230,423
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
DeLiver Pharma ApS has published its interim report for the period March 9, 2018 to December 31, 2018.
About DeLiver Pharma ApS
DeLiver Pharma ApS is a Danish company of the type Anpartsselskab based in Faaborg, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Niels Jonas Heilskov Graversen. The board consists of Jens Kristian Damsgaard (chair), Holger Jon Møller, Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. The company's owners include MOESTRUP HOLDING 2007 ApS, MØLLER HOLDING 2007 ApS and PHIDEAS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -20,487 and a net result of DKK -31,867 compared with DKK -21,682 the year before. Equity in the 2025 report amounted to DKK 163,221.